Biocryst Pharmaceuticals Inc BCRX
2 trading plans running, 13 Form 144 notices for $7.4M
10-Q, 10-K and Form 144What BCRX's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From Jun 18, 2024 to Dec 31, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired.
| Insider | What | Date | Reported in |
|---|---|---|---|
| Jon Stonehouse Member of the Board of Directors |
Adopted 10b5-1 plan | Mar 3, 2026 | 10-Q May 6, 2026 |
| Ron Dullinger Chief Commercial Officer |
Adopted 10b5-1 plan | Mar 2, 2026 | 10-Q May 6, 2026 |
| A. Machelle Sanders Member of the Board of Directors |
Adopted 10b5-1 plan | Aug 14, 2025 | 10-Q Nov 4, 2025 |
| Nancy J. Hutson, Ph.D. Director, Chair of the Board |
Adopted 10b5-1 plan | Jun 18, 2024 | 10-Q Aug 6, 2024 |
| Helen M. Thackray, M.D. Chief Research & Development Officer |
Ended 10b5-1 plan | Nov 8, 2023 | 10-K Feb 27, 2024 |
| Alane P. Barnes Chief Legal Officer and Secretary |
Ended 10b5-1 plan | Nov 7, 2023 | 10-K Feb 27, 2024 |
| Anthony J. Doyle Chief Financial Officer and Treasurer |
Ended 10b5-1 plan | Nov 7, 2023 | 10-K Feb 27, 2024 |
| Charles K. Gayer Chief Commercial Officer |
Ended 10b5-1 plan | Nov 7, 2023 | 10-K Feb 27, 2024 |
| Jon P. Stonehouse President and Chief Executive Officer |
Ended 10b5-1 plan | Nov 7, 2023 | 10-K Feb 27, 2024 |
Show the other 1 plans
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 8, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| May 18, 2026 | Amy McKee Director |
11,180 | $100K |
| May 13, 2026 | Barnes Alane P Officer |
62,500 | $596K |
| Mar 20, 2026 | HEGGIE THERESA Director |
49,933 | $505K |
| Mar 16, 2026 | Barnes Alane P Officer |
150,000 | $1.4M |
| Mar 2, 2026 | Stonehouse Jon P Director |
305,995 | $2.6M |
| Dec 22, 2025 | Barnes Alane P Officer |
21,773 | $167K |
| Dec 15, 2025 | Barnes Alane P Officer |
21,210 | $162K |
| Dec 3, 2025 | Barnes Alane P Officer |
19,770 | $151K |
| Dec 2, 2025 | Barnes Alane P Officer |
50,906 | $367K |
| Dec 1, 2025 | Barnes Alane P Officer |
91,004 | $644K |
| Nov 25, 2025 | Helen M Thackray Officer |
48,229 | $328K |
| Nov 21, 2025 | Helen Thackray Officer |
43,275 | $308K |
| Nov 13, 2025 | SANDERS MACHELLE Officer |
9,600 | $69K |
Show the other 5 notices
From the Form 144 XML filed with the SEC, since Nov 13, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BCRX/export.csv") into a cell.